Anzeige
Mehr »
Login
Freitag, 24.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PA31 | ISIN: US68621F1021 | Ticker-Symbol: 2PQ
Frankfurt
24.01.25
19:40 Uhr
3,360 Euro
0,000
0,00 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ORGANOGENESIS HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
ORGANOGENESIS HOLDINGS INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,3803,40020:40
3,3803,40020:34

Aktuelle News zur ORGANOGENESIS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
02.12.24Organogenesis Holdings Inc. - 8-K, Current Report1
22.11.24Organogenesis announces plans to expand manufacturing capacity1
22.11.24Organogenesis Holdings Inc.: Organogenesis Expands Manufacturing Capacity to Support Future Growth1
22.11.24Organogenesis Holdings Inc. - 8-K, Current Report-
15.11.24Organogenesis Holdings Inc.: Organogenesis Commends Final LCDs1
13.11.24Organogenesis Holdings Inc. - 8-K, Current Report1
12.11.24Organogenesis secures $130 million investment1
12.11.24Organogenesis announces $130M private placement offering3
ORGANOGENESIS Aktie jetzt für 0€ handeln
12.11.24Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock2
11.11.24Organogenesis Holdings Inc.: Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis142CANTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
► Artikel lesen
16.10.24Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 20242
01.10.24Organogenesis Holdings Inc.: Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers2
04.09.24Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September1
09.08.24Earnings call: Organogenesis exceeds Q2 revenue expectation at $130.2 million2
09.08.24Organogenesis files for mixed shelf offering of up to $250M1
08.08.24Organogenesis Holdings Inc. - 8-K, Current Report-
08.08.24Organogenesis Holdings Inc.: Organogenesis Shares ReNu® Program Update2
03.04.24Organogenesis Holdings Inc.: Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case179CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization...
► Artikel lesen
29.02.24Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance241CANTON, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1